It is an anti-Parkinsonian drug.
It acts as Catechol-O-Methyl Transferase (COMT) inhibitor and helping levodopa to reach the brain easily by reducing its biotransformation.
It works effectively if taken alongwith levodopa and carbidopa i.e. combination of levodopa, carbidopa and entacapone (LCE). It has also been found that this combination did not increase motor complications.
It is used in the treatment of Parkinson's disease. It has been found that prolonged treatment with entacapone results in enhanced response to levodopa in Patients of Parkinson's disease.
Hauser, R. A.; Panniset, M.; 2008. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Movement disorders, Vol. 24, No. 4, Pages 541-550.
Rinne, U. K., Larson, J. P. et al. 1998. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology, Vol. 51, No. 5. Pages. 1309-1314.